dc.contributor.author | Chazan, G | |
dc.contributor.author | Franchini, F | |
dc.contributor.author | Alexander, M | |
dc.contributor.author | Banerjee, S | |
dc.contributor.author | Mileshkin, L | |
dc.contributor.author | Blinman, P | |
dc.contributor.author | Zielinski, R | |
dc.contributor.author | Karikios, D | |
dc.contributor.author | Pavlakis, N | |
dc.contributor.author | Peters, S | |
dc.contributor.author | Lordick, F | |
dc.contributor.author | Ball, D | |
dc.contributor.author | Wright, G | |
dc.contributor.author | IJzerman, M | |
dc.contributor.author | Solomon, B | |
dc.date.accessioned | 2021-01-18T14:23:52Z | |
dc.date.issued | 2020-12 | |
dc.identifier.citation | ESMO open, 2020, 5 (6) | |
dc.identifier.issn | 2059-7029 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4292 | |
dc.identifier.eissn | 2059-7029 | |
dc.identifier.doi | 10.1136/esmoopen-2020-001090 | |
dc.description.abstract | Objectives: To report clinician-perceived changes to cancer service delivery in response to COVID-19. Design: Multidisciplinary Australasian cancer clinician survey in collaboration with the European Society of Medical Oncology. Setting: Between May and June 2020 clinicians from 70 countries were surveyed; majority from Europe (n=196; 39%) with 1846 COVID-19 cases per million people, Australia (AUS)/New Zealand (NZ) (n=188; 38%) with 267/236 per million and Asia (n=75; 15%) with 121 per million at time of survey distribution. Participants: Medical oncologists (n=372; 74%), radiation oncologists (n=91; 18%) and surgical oncologists (n=38; 8%). Results: Eighty-nine per cent of clinicians reported altering clinical practices; more commonly among those with versus without patients diagnosed with COVID-19 (n=142; 93% vs n=225; 86%, p=0.03) but regardless of community transmission levels (p=0.26). More European clinicians (n=111; 66.1%) had treated patients diagnosed with COVID-19 compared with Asia (n=20; 27.8%) and AUS/NZ (n=8; 4.8%), p<0.001. Many clinicians (n=307; 71.4%) reported concerns that reduced access to standard treatments during the pandemic would negatively impact patient survival. The reported proportion of consultations using telehealth increased by 7.7-fold, with 25.1% (n=108) of clinicians concerned that patient survival would be worse due to this increase. Clinicians reviewed a median of 10 fewer outpatients/week (including non-face to face) compared with prior to the pandemic, translating to 5010 fewer specialist oncology visits per week among the surveyed group. Mental health was negatively impacted for 52.6% (n=190) of clinicians. Conclusion: Clinicians reported widespread changes to oncology services, in regions of both high and low COVID-19 case numbers. Clinician concerns of potential negative impacts on patient outcomes warrant objective assessment, with system and policy implications for healthcare delivery at large. | |
dc.format | Print | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0 | |
dc.title | Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-10-24 | |
rioxxterms.versionofrecord | 10.1136/esmoopen-2020-001090 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc/4.0 | |
rioxxterms.licenseref.startdate | 2020-12 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | ESMO open | |
pubs.issue | 6 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 5 | |
pubs.embargo.terms | No embargo | |
dc.contributor.icrauthor | Banerjee, Susana | |